Original Research

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial

Sato Y, Fukuda N, Wang X, Urasaki T, Ohmoto A, Nakano K, Yunokawa M, Ono M, Sato Y, Mitani H, Tomomatsu J, Takahashi S

Cancer Management and Research 2020, 12:4161-4168

Published Date: 3 June 2020